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The ribbon isomer of α-conotoxin AuIB has 10-fold greater potency than the wild-type globular isomer at
inhibiting nicotinic acetylcholine receptors (nAChRs) in rat parasympathetic neurons, and unlike its
globular isoform, ribbon AuIB only targets a specific stoichiometry of the α3β4 nAChR subtype. Previous
electrophysiological recordings of AuIB indicated that ribbon AuIB binds to the α3(+)α3(−) interface
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(α3)2(β4)3. This specificity for a particular stoichiometry is remarkable and suggests that ribbon isoforms
of α-conotoxins might have great potential in drug design. In this study, we investigated the binding mode
and structure-activity relationships of ribbon AuIB using a combination of molecular modeling and
electrophysiology recording to determine the features that underpin its selectivity. An alanine scan
showed that positions 4 and 9 of ribbon AuIB are the main determinants of the interaction with (α3)3(β4)2
nAChR. Our computational models indicate that the first loop of ribbon AuIB binds in the "aromatic box" of
the acetylcholine orthosteric binding site, similar to that of globular AuIB. In contrast, the second loop and
the termini of the ribbon isomer have different orientations and interactions in the binding sites to those
of the globular isomer. The structure-activity relationships reported herein should be useful to design
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ABSTRACT
The ribbon isomer of α-conotoxin AuIB has 10-fold greater potency than the wild-type
globular isomer at inhibiting nicotinic acetylcholine receptors (nAChRs) in rat
parasympathetic neurons, and unlike its globular isoform, ribbon AuIB only targets a specific
stoichiometry of the α3β4 nAChR subtype. Previous electrophysiological recordings of AuIB
indicated that ribbon AuIB binds to the α3(+)α3(−) interface within the nAChR extracellular
domain, which is displayed by the (α3)3(β4)2 stoichiometry but not by (α3)2(β4)3. This
specificity for a particular stoichiometry is remarkable and suggests that ribbon isoforms of αconotoxins might have great potential in drug design. In this study, we investigated the
binding mode and structure-activity relationships of ribbon AuIB using a combination of
molecular modeling and electrophysiology recording to determine the features that underpin
its selectivity. An alanine scan showed that positions 4 and 9 of ribbon AuIB are the main
determinants of the interaction with (α3)3(β4)2 nAChR. Our computational models indicate
that the first loop of ribbon AuIB binds in the “aromatic box” of the acetylcholine orthosteric
binding site, similar to that of globular AuIB. In contrast, the second loop and the termini of
the ribbon isomer have different orientations and interactions in the binding sites to those of
the globular isomer. The structure-activity relationships reported herein should be useful to
design peptides displaying a ribbon α-conotoxin scaffold for inhibition of nAChR subtypes
that have hitherto been difficult to selectively target.
Abbreviations
ACh, acetylcholine; AChBP, acetylcholine-binding protein; ECD, extracellular domain;
gAuIB, globular AuIB; ICD, intracellular domain; nAChR, nicotinic acetylcholine receptor;
rAuIB, ribbon AuIB; SAR, structure-activity relationship; TMD, transmembrane domain
Keywords: Conotoxin; Nicotinic acetylcholine receptor; Biological activity; Molecular
modeling
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Introduction
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated cationselective ion channels that belong to the Cys-loop family of receptors [1]. Neuronal nAChRs
are homo- or heteropentamers of α2–α10 and β2–β4 subunits, and the different pentameric
isoforms are differentially expressed in different parts of the brain [2,3]. Neuronal nAChR
isoforms are involved in a range of diseases and conditions, including Alzheimer’s disease,
Parkinson’s disease, schizophrenia, epilepsy, nicotine addiction, anxiety, depression and pain
[3].
Heteropentameric nAChRs can assemble into different stoichiometries, with some
displaying diverse pharmacological and biophysical properties [3]. For example, the α4β2
nAChR subtype, which is the most abundant nAChR subtype in the human brain, exists in
two main stoichiometries: (α4)2(β2)3 and (α4)3(β2)2 [4]. These two stoichiometries have
contrasting pharmacological properties: the (α4)2(β2)3 has a long open lifetime and is
insensitive to the agonist NS-9283, whereas the (α4)3(β2)2 has a short open lifetime and is
potentiated by NS-9283 [4]. Subunit stoichiometries of other nAChR subtypes such as the
α3β4, α7β2 and α9α10 nAChR have also been reported [5–7]. Although the various subunit
stoichiometries of these nAChR subtypes have disparate functions, the relationship between
the different functions and pathophysiology states remains unknown, mostly because
detecting nAChR subtype stoichiometries is challenging. In this study we established some
groundwork on the structure-activity relationship (SAR) of the ribbon isoform of α-conotoxin
AuIB (rAuIB) [8,9], which specifically inhibits one of the two major stoichiometries of the
α3β4 nAChR [10].
Structurally, nAChRs are composed of three domains: an extracellular domain (ECD),
a transmembrane domain (TMD), and an intracellular domain (ICD), as shown in Fig. 1
[1,11]. Acetylcholine (ACh) binds at the interface between two subunits in the ECD,
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triggering the opening of the channel [1]. Each subunit in the ECD is composed of one αhelix, which lines the pore, and two β-sheets made of 10 β-strands (Fig. 1A and B). The ACh
orthosteric binding site is located at the interface between two subunits in the ECD; the
“principal” subunit, denoted (+), contacts the agonist with the A-, B- and C-loops, and the
“complementary” subunit, denoted (−), contributes to the ACh binding site through the βstrands 2, 5 and 6 (Fig. 1B). Functional binding sites cannot be formed with β subunits as the
principal subunit; therefore the number of functional binding sites displayed by
heteropentameric nAChRs depend on their stoichiometries. As illustrated in Fig. 1C, the
(α3)2(β4)3 nAChR subtype has two α3(+)β4(−) functional binding sites, and the (α3)3(β4)2
subtype has an additional functional binding site between two α3 subunits, i.e. α3(+)α3(−) [6].
Concatemeric assemblies of α3 and β4 subunits with the arrangements described in Figure 1C
were reported to have similar pharmacological properties to subtypes assembled freely from
subunits expressed in oocytes [12]. We note that in the current study we focused on
engineered α3-containing nAChRs of these compositions but in native tissue the ganglionic
nAChRs are more complex and could include accessory subunits of α3, α5, α6, β2 or β4 [13].
Conotoxins are a large family of disulfide-rich peptides isolated from the venom of
marine cone snails [14,15]. Due to their potency and exquisite selectivity for ion channels and
transporters of the nervous system, these peptides are considered as valuable pharmacological
tools and drug leads [16]. The largest characterized pharmacological class of conotoxins are
the α-conotoxins, which inhibit nAChRs and typically have 12−20 amino acid residues
[14,16]. Because of their small size, α-conotoxins can readily be chemically synthesized, and
their selectivity and potency against important nAChR subtypes make them interesting
candidate drug leads [16–18]. Most α-conotoxins have the cysteine pattern CC-C-C,
corresponding to the conotoxin cysteine Framework I. These conotoxins are further classified
into m/n groups according to the length of the two loops, which are defined as the segments
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between Cys II and Cys III (loop 1, m residues) and between Cys III and Cys IV (loop 2, n
residues) [19,20]. The four Cys residues can theoretically form three disulfide connectivities,
resulting in the globular isomer (Cys I-III, Cys II-IV), ribbon isomer (Cys I-IV, Cys II-III) or
bead isomer (Cys I-II, Cys III-IV) (Fig. 1D). The globular isomer is typically displayed by
wild-type α-conotoxins isolated from venoms, apart from one instance where the ribbon
connectivity of an α-conotoxin was detected in the venom of Conus imperialis [21]. Some
ribbon isomers are as active as or more potent than the globular isomer at inhibiting nAChRs,
and consequently display altered pharmacological properties [8,22].
α-Conotoxin AuIB (Fig. 1D and E) belongs to the 4/6 class of conotoxins [9], and the
globular form (gAuIB) inhibits the rat α3β4 nAChR with an IC50 of 1−3 µM [10]. rAuIB was
the first ribbon isomer reported to have higher potency than the globular isomer, with rAuIB
displaying a 10-fold improved inhibition of Ach-evoked current in rat parasympathetic
neurons compared to gAuIB, with IC50s of 0.1 nM and 1.2 nM, respectively [8]. However,
another study reported that gAuIB was more potent than rAuIB at inhibiting rat α3β4 nAChR
expressed in Xenopus laevis oocytes [23]. These apparently conflicting results were explained
by a switch in the major stoichiometry of the α3β4 nAChR when expressed in mammalian
cells compared to X. laevis oocytes [6]. AuIB isomers were shown to have differential
sensitivity to the two stoichiometries of the α3β4 nAChR: gAuIB inhibited the (α3)3(β4)2
nAChR (transfected at 10:1 ratio) and (α3)2(β4)3 nAChR (1:10 ratio) with IC50s of 1.1 µM and
3.0 µM, respectively; whereas rAuIB inhibited the (α3)3(β4)2 nAChR with an IC50 of 0.86 µM
and was inactive at the other stoichiometry [10]. Therefore, rAuIB only inhibited the
stoichiometry displaying an α3(+)α3(−) binding site, indicating that it binds at the interface
between two α3 subunits. Conotoxin rAuIB can therefore potentially be used to identify a
single subtype and stoichiometry among all α3β4 subtypes expressed in vivo.
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As the α3β4 nAChR subtype is involved in a range of drug addictions, (e.g. for
morphine [24], methamphetamine [25] and nicotine [26–28]), and the β4 subunit is linked to
anxiety behavior [29], these receptors are of considerable pharmaceutical interest. Thus, highaffinity molecular probes are required to tease apart the neurological functions of the two
main α3β4 nAChR stoichiometries. Here, we investigated the SAR and binding mode of
rAuIB on the rat α3β4 nAChR putatively expressed as (α3)3(β4)2 stoichiometry from the
injection of 10:1 α3:β4 RNA ratio. This is the first detailed SAR study of the binding mode of
a ribbon α-conotoxin.

Materials and methods
2.1 Peptide synthesis and cleavage
A suite of 13 AuIB peptides (gAuIB, rAuIB, 10 Ala variants of rAuIB and
[P7A]gAuIB) was synthesized using Fmoc solid phase peptide synthesis (SPPS) on a rink
amide resin (Novabiochem®, Merck, Kenilworth, NJ, USA), with the side chains of Cys
residues protected in pairs using orthogonal protective groups, which were then selectively
removed in different oxidation solutions. For this purpose, we used the acid labile trityl (Trt)
group to protect Cys II and Cys III, and the S-acetamidomethyl (Acm) group to protect Cys I
and Cys IV for rAuIB and its mutants. Likewise for gAuIB, the Trt group was used to protect
Cys II and Cys IV, and the Acm group was used to protect Cys I and Cys III. All crude linear
peptides were cleaved and deprotected in a cleavage cocktail comprising 96% trifluoroacetic
acid (TFA, Auspep, VIC, Australia), 2% H2O and 2% triisopropylsilane (v/v) for 2 h. The
crude peptides were purified by HPLC using a gradient of 0−50% buffer B (0.045% TFA in
90% acetonitrile [Merck]) over 50 min and monitoring at 214/280 nm. The same method was
also used in subsequent purifications.
A two-step oxidative folding was used to form the disulfide bonds; the first disulfide
bond was formed by adding peptides (80 mg crude peptide dissolved in 100 mL water) into an
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equal volume of 20 mM potassium ferricyanide, 0.1 M Tris, pH 7.5 for 1 h. The reaction
mixture was frozen and lyophilized overnight, and the second disulfide bond was formed by
adding 50 mL of 0.1 M iodine solution for 1 h. All Fmoc-amino acids were from Chem-Impex
International (Wood Dale, IL, USA). All organic reagents and solvents, unless stated
otherwise, were purchased from Sigma-Aldrich (St Louis, MO, USA).
2.2 Nuclear magnetic resonance (NMR) spectroscopy
With a few exceptions, where crystallization has been possible [30], NMR is the
preferred technique for conotoxin structural characterization. Two-dimensional total
correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY)
spectra of rAuIB, gAuIB and the variants were acquired using an Avance-600 MHz NMR
spectrometer (Bruker) with mixing times of 80 ms and 200–300 ms, respectively. The αproton (Hα) chemical shifts of synthetic peptides were assigned using CcpNmr analysis
(version 2.4.1). Subsequently, the differences between the observed Hα chemical shifts and
those of the corresponding residues in a random coil peptide [31], referred to as secondary Hα
chemical shifts, were calculated to provide information on folding and secondary structure, as
has been widely applied for other conotoxins [32].
2.3 In vitro cRNA synthesis
Plasmid constructs of rat α3 (pT7TS) and β4 (pNKS2) nAChR subunits were
linearized with the XbaI restriction enzyme (NEB, Ipswich, MA, USA) for in vitro cRNA
transcription using the T7/SP6 mMessage mMachine® transcription kits (AMBION, Forster
City, CA, USA).
2.4 Oocyte preparation and microinjection
Stage V–VI oocytes were obtained from X. laevis, defolliculated with 1.5 mg/mL
collagenase Type II (Worthington Biochemical Corp., Lakewood, NJ, USA) at room
temperature (21−23 °C) for 1−2 h in OR-2 solution (82.5 mM NaCl, 2 mM KCl, 1 mM
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MgCl2 and 5 mM HEPES at pH 7.4). Oocytes were injected with 5 ng cRNA of rat α3β4
nAChR (α3:β4 = 10:1; concentration confirmed spectrophotometrically and by gel
electrophoresis) using glass pipettes pulled from glass capillaries (3-000-203 GX, Drummond
Scientific Co., Broomall, PA, USA). Oocytes were incubated at 18 °C in sterile ND96
solution (96 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES at pH 7.4),
supplemented with 5% fetal bovine serum, 0.1 mg/mL gentamicin (Gibco, Grand Island, NY,
USA) and 100 U/mL penicillin-streptomycin (Gibco, Grand Island, NY, USA).
2.5 Oocyte two-electrode voltage clamp recording and data analysis
Electrophysiological recordings were carried out 2−5 days post cRNA microinjection.
Two-electrode voltage clamp recordings were performed at room temperature using a
GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale,
CA, USA) at a holding potential of −80 mV. Voltage-recording and current-injecting
electrodes were pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus, Holliston,
MA, USA) and filled with 3 M KCl, giving resistances of 0.3–1 MΩ. Oocytes were perfused
with ND96 solution using a continuous Legato 270 push/pull syringe pump perfusion system
(KD Scientific, Holliston, MA, USA) at a rate of 2 mL/min.
Initially, oocytes were briefly washed with ND96 solution followed by three
applications of 50 µM ACh for rat α3β4 nAChR (α3:β4 = 10:1) [10]. Washout with bath
solution was done for 3 min between ACh applications. Oocytes were incubated with peptides
for 5 min with the perfusion system turned off, followed by co-application of ACh and
peptide with flowing bath solution. All peptide solutions were prepared in ND96 solution
containing 0.1% bovine serum albumin. Peak current amplitudes before (ACh alone) and after
(ACh + peptide) peptide incubation were measured using AxoGraph X software (Axograph
Scientific, Berkeley, CA, USA), where the ratio of ACh + peptide-evoked current amplitude
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to ACh alone-evoked current amplitude was used to assess the activity of the peptides at the
rat α3β4 nAChR.
All electrophysiological data were pooled (n ≥ 3) and represent means ± standard error
of the mean. Data sets were compared using an unpaired Student’s t-test (GraphPad Software,
La Jolla, CA, USA). Differences were regarded statistically significant when p < 0.05. The
IC50 was determined from concentration-response curve fitted to a non-linear regression
function and reported with error of the fit.
2.6 Molecular modeling
Molecular models of the interaction between AuIB and the ECD of rat α3β4 nAChR
were built by homology with Modeller9v18 [33] using the following crystal structures as
templates: (1) the complex between Aplysia californica acetylcholine-binding protein
(AChBP) and conotoxin PnIA variant (PDB: 2BR8), and (2) the human α4β2 nAChR (PDB:
5KXI). The complex between rAuIB and the ECD of (α3)3(β4)2 nAChR was modelled by
assuming an interaction in the α3(+)α3(−) orthosteric binding site whereas the complex
between gAuIB and the ECD of (α3)2(β4)3 nAChR was built by assuming an interaction in the
α3(+)β4(−) orthosteric binding site. Similar to most other α-conotoxins rAuIB is a
competitive inhibitor of the α3β4 nAChR, suggesting that it binds in the orthosteric binding
site [10]. In contrast, α-conotoxin gAuIB inhibits non-competitively the α3β4 nAChR [10] but
it was shown to nevertheless bind to the orthosteric binding site [34]. This latter study
unequivocally

identified

that

gAuIB

binds

at

the

α3(+)β4(−)

interface

using

electrophysiological recording of nAChRs expressing β4 subunit mutants. As an explanation
to the non-competitive nature of the inhibition, gAuIB was proposed to stabilize the
desensitized state of α3β4 nAChR [34]. It was previously demonstrated using single channel
recording that another antagonist, DHβE, stabilized the desensitized state of an nAChR [35],
despite binding in the orthosteric binding site [36].
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The molecular models were refined by a 50 ns molecular dynamics simulation in
explicit water using the GROMACS 5.1.4 package [37] and the Amber99SB-ILDN protein
force field [38], as described previously [39,40]. Briefly, the systems were gradually heated
from 50 to 300 K at constant volume and then simulated with constant pressure while
gradually removing the restraints imposed on the protein and peptide atoms. All bonds
involving hydrogen atoms were constrained with the LINCS algorithm, allowing the use of a
2 fs time step. The particle-mesh Ewald method was used to compute long-range electrostatic
interactions. The models of complexes involving two rAuIB mutants, [S4A]rAuIB and
[F9A]rAuIB, were initially generated by substituting residue side chains using Modeller9v18
and then carrying out molecular dynamics simulations as described above. The backbone
root-mean-square deviation from the starting conformation was stable over the last 20 ns of
the simulations and this period was used for analysis. The solvent accessible surface area was
calculated using the GROMACS package with a probe radius of 1.4 Å. Additional 200 ns
molecular dynamics simulations were also carried out using similar set-up for rAuIB and
[P7A]rAuIB in the absence of the receptor. Secondary structure analyses of these simulations
were computed using the DSSP program [41] and the GROMACS package.

Results
3.1 Peptide synthesis and oxidative folding
We designed a suite of mutants in which all non-Cys residues of rAuIB were
separately substituted by Ala to identify the positions that are important for inhibition of the
α3β4 nAChR (Table 1). All the Ala mutants of rAuIB as well as rAuIB, gAuIB and
[P7A]gAuIB were successfully synthesized with orthogonal protection of the cysteine side
chains to orient the folding toward a unique disulfide isomer.
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3.2 [P7A]rAuIB has more similar secondary Hα chemical shifts to gAuIB than rAuIB
Secondary Hα chemical shifts analysis, which is useful for deducing secondary
structure elements, was conducted for gAuIB, rAuIB and all mutants (Fig. 2). The Hα
secondary chemical shifts of rAuIB synthesized in this study were in agreement with
previously reported values [8], indicating that the fold of rAuIB is the same as in previous
studies. Apart from some local changes in chemical shift at the substitution site, all mutants
displayed a similar pattern of shifts to the parent peptide except [P7A]rAuIB (Fig. 2C).
Interestingly, residues from Pro6 to Phe9 of [P7A]rAuIB had negative secondary Hα chemical
shifts (Fig. 2C), indicating that this segment adopts an α-helical structure, a motif that exists
in the globular isomer but not in the ribbon isomer. The P7A substitution therefore seems to
have improved the definition of the structure of rAuIB, with the parent peptide being devoid
of stable regular secondary structure. The retention time and secondary Hα chemical shifts
between [P7A]rAuIB and [P7A]gAuIB were different, excluding the possibility that
[P7A]rAuIB converted into [P7A]gAuIB during the folding process (Fig. 2D). To further
substantiate this difference of conformation, we carried out two 200 ns molecular dynamics
simulations: one simulation starting from the NMR solution structure of rAuIB, and the
second from a model of the P7A variant, which was created by simple side chain swaps in the
NMR structure of rAuIB. Consistent with the NMR measurements, the simulation of
[P7A]rAuIB suggested the existence of a stable α-helix from Pro6 to Phe9 (Fig. 2E).
Interestingly, the P7A variant was more rigid than the parent peptide, as measured using the
root-mean-square fluctuation (Fig. 2F).
3.3 Several rAuIB analogues have decreased potency at rat α3β4 nAChR
All peptides were tested for inhibition of the rat α3β4 nAChR subtype heterologously
expressed in X. laevis oocytes. In the first round of electrophysiological experiments, all
rAuIB Ala mutants were tested at 1 µM (corresponding to the reported IC50 of rAuIB [10])
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and gAuIB was tested at 3 µM, resulting in 30–40% inhibition of ACh-evoked currents of rat
α3β4 (α3:β4 = 10:1) nAChR (Fig. 3A). The rAuIB Ala mutants exhibited comparable activity
to the parent peptide except for [S4A] and [F9A]rAuIB, which caused 25% and 20%
inhibition, respectively (Fig. 3A). Comparison of the rat α3β4 nAChR inhibition by [S4A]
and [F9A]rAuIB indicates that the difference was not statistically significant. In the second
round, all peptides were tested at 100 µM, inhibiting 35–55% of ACh-evoked currents of rat
α3β4 (α3:β4 = 10:1) nAChR (Fig. 3A). Mutation at S4, P6, F9, T11, N12 and D14 caused a
decrease in activity, ca. 40% inhibition, whereas other peptides had higher activity, with 45–
55% inhibition (Fig. 3B and C). The efficacy (maximum inhibition of ACh-evoked currents)
of rAuIB was ~55%, which is ~15% lower than reported previously [10]. This difference may
arise from variations in the relative levels of expression of α3 and β4 subunits in different
batches of oocytes.
In summary, none of the single position variants displayed a dramatic loss of activity
compared to the parent peptide. The Ala substitution of six positions in rAuIB led to a
decreased activity at high concentration, but only two substitutions, S4A and F9A,
significantly impacted activity at a concentration similar to the IC50 of rAuIB, suggesting they
are more important for antagonizing the activity of rat α3β4 nAChR. To better quantify the
loss of activity, we calculated the IC50 of [S4A]rAuIB at the α3β4 nAChR (α3:β4 = 10:1) to
be 442 ± 99 nM (Fig. 3D); the IC50 of rAuIB was previously reported to be 860 nM at the
same

receptor

stoichiometry [10].

Considering

the

variability

between

different

electrophysiological set-ups, we consider that inhibition by rAuIB and [S4A] rAuIB are of the
same order of magnitude, i.e., the S4A substitution caused a less than 10-fold drop decrease in
inhibition.
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3.4 rAuIB adopts a binding mode similar to that of globular α-conotoxins
Since the functional data indicated that rAuIB inhibits the α3(+)α3(−) interface of the
(α3)3(β4)2 nAChR [10] we built molecular models of the interaction between the α3(+)α3(−)
binding site and rAuIB. This model was refined using molecular dynamics simulations and
used to propose explanations for the SAR data. A molecular model of the interaction between
gAuIB and the α3(+)β4(−) binding site was built similarly to that of rAuIB for comparison
purposes. The molecular interactions between the peptides and the receptors were monitored
over the last 20 ns of each 50 ns simulation. This period of 20 ns, during which the system
reached equilibrium, is referred to as the “simulation time”.
3.4.1 Binding mode of gAuIB at the rat α3β4 nAChR

The G1A, P6A and F9A mutants of gAuIB are reported to display decreased inhibitory
activity at rat α3β4 nAChR compared to gAuIB [34]. The molecular model of the complex
between gAuIB and the α3(+)β4(−) binding site (Fig. 4A), which is very similar to a reported
molecular model of the same system [34], can be used to suggest rational explanations to the
consequence of these substitutions. The positively charged N-terminus (Gly1) is in the
proximity of the negatively charged side chain oxygen atoms of D168 and D169 in the
simulation, with an average distance of 3.9 Å and 2.8 Å. A stable salt bridge was established
between D169 and the N-terminus during the simulation time and a similar interaction was
transiently formed between D169 and the N-terminus. Therefore, a substitution of this first
residue of the toxin by Ala could change the peptide backbone conformation and prevent the
establishment of these salt bridges.
Pro6 is a highly conserved residue among α-conotoxins because it anchors the
conotoxins into an aromatic pocket on the nAChR that is important for the interaction
between nAChR and agonists [42]. It is therefore not surprising that the substitution of Pro6
by Ala caused a decrease in activity. The side chain of Phe9 is embedded in a hydrophobic
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pocket formed by K57, E59, Q117 and L119 of the β4 subunit, and the backbone oxygen of
Phe9 formed a hydrogen bond with the receptor Q117 during 85% of the simulation time. The
substitution of the bulky Phe9 by an Ala, which has a smaller side chain, would cause a
change in shape complementarity at the interface, possibly resulting in a reorientation of the
peptide in the binding pocket (similar to [F9A]rAuIB described below).
3.4.2 Binding mode of rAuIB at the rat α3β4 nAChR

Our molecular models suggest that the conformation adopted by rAuIB when bound to
the rat α3β4 nAChR is similar to that of gAuIB except for the N- and C- termini (Fig. 4B).
The interactions established by the first loop of AuIB are similar for the two isomers, and this
loop sits deeply in the orthosteric binding site of the α3β4 nAChR. The first disulfide bond
(i.e., Cys I-Cys III for gAuIB and Cys I-Cys IV for rAuIB) packs similarly against the vicinal
disulfide bond of the C-loop, and this interaction is a conserved feature in the crystal
structures of α-conotoxins/AChBP. Because of this interaction, the different disulfide
connectivities of the two isomers resulted in different peptide conformation and disparate
location of their N- and C- termini within the nAChR binding site. The charged N-terminus,
(Gly1) interacts with the acidic residues of the F-loop of α3β4 nAChR in the gAuIB model
(Fig. 4A) but not in the model of rAuIB (Fig. 4B). The location of the amidated C-terminus in
the nAChR binding site is also different between the two isomers; this difference results from
the different conformation of the second loop.
We have shown the side chains of Ser4 and Phe9 in rAuIB are the most important for
activity at the rat α3β4 nAChR. As shown in Fig. 4B, Ser4 of rAuIB establishes a stable side
chain-side chain hydrogen bond with D169 (98% of the simulation time). Additionally, Ser4
forms transient hydrogen bonds with S36 and N166 (40% of the simulation time). Phe9 of
rAuIB interacts with the α3(−) subunit: it forms a hydrogen bond with K57 through its
backbone oxygen during 93% of the simulation and its side chain contacts the residues E34,
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S36, W55, K57 and I119. The distance between the heavy atoms of Phe9 and of the
aforementioned residues of the α3(−) subunit were below 5.0 Å, the distance considered to
define a contact.
Positions 11, 12 and 14 of rAuIB caused a small drop of inhibition when mutated to
Ala. These three residues are located at the interface with the receptor in the binding model
but their side chains are also solvated, suggesting that their contribution to the electrostatic
component of the binding energy is at best weak. Indeed, their involvement was only detected
experimentally at the highest concentration (100 µM). By contrast, the impact of the
substitutions S4A and F9A were detected at the lower concentration of 1 µM. We further
studied the impact of these two substitutions on the binding mode by carrying out further
molecular dynamics simulations.
3.4.3 Binding mode of [S4A]rAuIB at the rat α3β4 nAChR

The binding mode resulting from the 50 ns molecular dynamics simulation of
[S4A]rAuIB displayed subtle variations from that of the parent peptide, with differences
mainly located in the proximity of the modified position 4 (Fig. 4C). Besides position 4, all
positions at the interface with the β4 subunit, such as Phe9, established similar molecular
interactions in the S4A mutated model. The simulation suggests that the loss of the hydrogen
bond between Ser4 and D169 is compensated by the establishment of a hydrogen bond
between the side chain of α3(−) K168 and the backbone oxygen of the toxin Cys2, which was
stable for 89% of the simulation time. The conformation of the side chain of K168 of the
receptor seems to be also stabilized by electrostatic interactions with the D169 side chain.
This electrostatic interaction was not possible in the rAuIB model because D169 was engaged
in a hydrogen bond with Ser4 and consequently maintained away from K168 (Fig. 4B and C).
The transient hydrogen bonds between Ser4 and α3(−) S36/N166 established in the model of
rAuIB were not compensated in the mutated model of [S4A]rAuIB. Therefore, we suggest
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that [S4A]rAuIB displays overall fewer hydrogen bonds with the receptor than the parent
peptide. Based on electrophysiological measurements, we proposed that the decrease in
activity was lower than 10-fold, corresponding to a loss of less than 1.4 kcal/mol. This energy
is typical of a weak hydrogen bond interaction, which is consistent with the 40% occurrence
of the hydrogen bonds between Ser4 and S36/N166 during the molecular dynamics
simulations.
3.4.4 Binding mode of [F9A]rAuIB at the rat α3β4 nAChR

According to the molecular model of rAuIB bound to the α3(+)α3(−) binding site,
Phe9 is buried at the interface with the receptor. Its substitution by Ala creates a gap between
the α3(−) subunit and the peptide in the initial step of the simulation. During this simulation,
the peptide reoriented slightly in the binding site, resulting in several changes of pairwise
interactions and a slight outward reorientation of the C-loop (Fig. 4D). Globally, the F9A
variant had fewer contacts with the receptor than the parent peptide, as evidenced by a
decrease in buried surface area from 1646 Å2 to 1452 Å2. As a result of the slight shift in
orientation, the backbone oxygen of Ala9 only forms a transient hydrogen bond (42% of the
simulation time) with the side chain of K57, whereas this interaction was present during 93%
of the simulation time for the parent peptide. Similarly, the hydrogen bond between Ser4
(rAuIB) and D169 (α3 subunit) of the receptor was only observed during 75% of the
simulation time compared to 98% for the parent peptide. We therefore propose that the F9A
substitution caused a slight shift of the binding mode, resulting in fewer contacts and
hydrogen bonds at the interface.

Discussion
The surprising discovery that the ribbon isomer of an α-conotoxin displays higher
potency than the corresponding globular isomer [8] contrasts with the previously held
assumption that native (globular) disulfide isomers have optimal activity. We carried out a
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complete Ala scan of rAuIB, discovering the side chains of two positions, Ser4 and Phe9,
were the most important for activity against the rat α3β4 nAChR. We have rationalized these
data by proposing a binding mode between rAuIB and α3β4 nAChR. Molecular dynamics
simulation suggested that rAuIB adopts a well-defined conformation when bound to its
molecular target and that the binding mode is highly stable. A number of other SAR studies
have been conducted on globular α-conotoxins [14], and we compared our results to these
studies to further evaluate the molecular model of rAuIB binding mode.
Position 1 was identified to be important for gAuIB activity at the α3β4 nAChR [34]
but this was not the case for rAuIB (this study), paralleling the contrasting role of this position
observed in several other studies on α-conotoxins. As for rAuIB, the G1A substitution had no
impact on the inhibition of α7 nAChR by α-conotoxin ImI [43], and a minor impact on the
affinity of α-conotoxin MII for the α3β2 nAChR (< 5-fold difference) [44]. A molecular
model of the interaction between ImI and the α7 nAChR indeed suggested that ImI Gly1 does
not interact with the receptor [40], similar to our model of the rAuIB/α3β4 nAChR complex.
In contrast, the G1A mutation of α-conotoxin TxID resulted in a ~20-fold decreased activity at
the α3β4 nAChR [45], and the same substitution caused a significant decrease in activity for
α-conotoxin gAuIB at the α3β4 nAChR [34]. The molecular models of the corresponding
complexes suggested that the N-terminus of these peptides potentially forms a salt bridge with
negatively charged residues located in the F-loop of the receptor [34,45], as in our model of
the gAuIB/α3β4 nAChR complex.
The S4A substitution impacted the activity of rAuIB at the α3β4 nAChR, but it was
reported not to affect that of gAuIB [34]. As for gAuIB, this substitution had no effect on the
activity or affinity of α-conotoxin RgIA at α9α10 [46], ImI at α7 [43,47], PeIA at α3β2 and
α6/α3β2β3 [48], BuIA at α6/α3β2β3 [49] and TxID at α3β4 nAChRs [45]. Only a small
decrease of inhibition of five- to eight-fold was reported after a substitution equivalent to S4A
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in GID* (S7A for GID*) and MII at the α4β2 and α3β2 nAChRs, respectively [44,50,51].
TxID Ser4 was suggested to have no interaction with the receptor using molecular modeling,
explaining that its substitution to Ala was innocuous [45]. In contrast, a molecular model of
the complexes involving GID* and the α4β2 nAChR suggested that the Ser side chain
potentially forms a hydrogen bond with an Asp residue in the F-loop of the receptor [52],
similar to our model of the rAuIB/α3β4 nAChR complex.
Pro6 is highly conserved among all α-conotoxins and typically interacts with the
aromatic box, which is a conserved ACh interaction site in the nAChR and AChBP orthosteric
binding sites [53–55]. Pro6 is also important for stabilizing the structure of globular αconotoxins: replacing this Pro with Ala typically results in a change of conformation linked to
a decrease or loss of activity. For example, the P6A substitution of α-conotoxin PeIA caused a
20-fold decrease of inhibition of the α6/α3β2β3 nAChR compared to the parent peptide [48].
The P6A substitution of α-conotoxins ImI and MI resulted in a 50–70 fold decrease in affinity
for the α7 and muscle type nAChRs, respectively [43,47,56], whereas this substitution caused
a >700-fold decrease in activity for α-conotoxin MII at the α3β2 nAChR [44,50]. The same
substitution resulted in a loss of helical content for globular Vc1.1 and a marked decrease in
inhibitory activity of α-conotoxin Vc1.1 [57]. Similarly, the P6A substitution of gAuIB
resulted in a decrease in secondary structure content as well as a complete loss of inhibitory
activity [34]. In contrast, [P6A]rAuIB showed only a small decrease in activity compared to
the parent peptide. Our molecular models suggest that Pro6 of rAuIB and gAuIB should make
similar interactions with the receptor and we propose that the different impact that P6A
substitution had on the activity of the two peptides arises from its differential effect on the
peptide structures. Indeed, P6A substitution destabilizes the small α-helical motif required for
the activity of gAuIB. In contrast, as rAuIB already lacks regular secondary structure, P6A
does not further impact its propensity to adopt the α-helical content required for binding to the
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receptor. The substantial decrease in inhibitory activity of gAuIB resulting from P6A
substitution appears therefore to result primarily from the change of conformation of the
peptide rather than decreased interactions of the position 6 side chain at the interface.
The only rAuIB variant that displayed different Hα secondary chemical shifts from the
parent peptide was [P7A]rAuIB, indicating that this variant adopts a different fold in solution.
NMR spectroscopy data suggest that [P7A]rAuIB adopts a helical structure, whereas rAuIB
lacked regular secondary structure and was globally less structured. A possible explanation for
this change of conformation is that Ala residues promote the formation of α-helices, whereas
Pro residues typically destabilize regular secondary structure elements. BuIA is the only other
α-conotoxin that has a similar cysteine scaffold to AuIB and had its ribbon isomer studied by
NMR spectroscopy [58]. As for ribbon AuIB, ribbon BuIA displays Pro residues at positions 6
and 7. The ribbon isomer of BuIA also has a more flexible backbone than the globular isomer
and does not form the α-helix that is a conserved feature of α-conotoxin globular isomers. It
would be interesting to study the influence of the P7A substitution on the structure of ribbon
BuIA because this substitution could increase the helical content similarly to rAuIB. In our
molecular models, rAuIB interacts with the receptor using a conformation that is stabilized by
the P7A substitution, suggesting that the binding energy of the variant would benefit from a
more favourable entropy term than the parent peptide. Nevertheless, the activity of the mutant
was not experimentally different from the parent peptide, which could be interpreted by the
loss of a number of contacts between the Pro side chain and the receptor.
The substitution of position 9 with Ala caused a decrease in affinity for both gAuIB
[34] and rAuIB (this work). Position 9 of globular α-conotoxins is buried at the interface with
the complementary subunit and has been identified as important for modulating the activity of
a range of globular α-conotoxins [34,45,46,49,51,57]. For example, Ala mutation at this
position caused a 50-fold decrease in activity of α-conotoxin GI at the muscle type nAChR
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[59], a 20–30 fold decrease in affinity of α-conotoxin MII at α3β2 nAChR [44,50], and a >17fold decrease in activity of α-conotoxin GID* at α4β2 nAChR [51]. In addition, the R9A
substitution resulted in a 1500-fold decrease in activity of RgIA at α9α10 nAChR [46].
Substitution of position 9 can also enhance activity, with the [S9A]PeIA displaying three-fold
lower IC50 than the parent peptide at the α3β2 nAChR [48] and the [N9W]Vc1.1 and
[N9A]Vc1.1 increasing activity by 20- and 30-fold at the human α9α10 nAChR compared to
Vc1.1, respectively [39,57]. Several molecular models have been built to explain the ability of
α-conotoxin position 9 to modulate nAChR inhibition, which suggest this residue interacts
with various positions of the complementary subunit depending on the conotoxin and nAChR
subtype [39,52,60]. In the proposed binding mode of rAuIB, Phe9 mainly interacts with β4
K57, whereas GID* Arg12 was proposed to interact with β2 position 59 [52], [N9W]Vc1.1
Trp9 with α10 W118 [39] and RgIA Arg9 with α10 W81 [60].
In summary, we have identified a number of positions crucial for the activity of the
ribbon isomer of AuIB that are also important for the activity of gAuIB and/or other globular
α-conotoxins, indicating rAuIB has a globally similar binding mode to the globular isomers of
α-conotoxins. According to our models, the main difference between the ribbon and globular
AuIB at the interface with α3β4 nAChR is at their N- and C- termini. Changing the disulfide
connectivity of α-conotoxins from a globular to ribbon isomer therefore does not introduce a
dramatic change of binding mode at the interface with the receptor but it does create some
different interactions that can have a substantial impact on the selectivity, as is the case for
AuIB. Ribbon isomers should therefore be more systematically considered in the design of
molecular probes and specific inhibitors of nAChR subtypes based on α-conotoxins.
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Figure legends
Fig. 1. Overview of the three-dimensional structure of nAChRs, the two main stoichiometries
of α3β4 nAChRs, the three disulfide isomers of AuIB and the NMR spectroscopy solution
structures of ribbon AuIB (rAuIB) and globular AuIB (gAuIB). A: The structure of nAChRs
comprises three domains: an extracellular domain (ECD), a transmembrane domain (TMD),
and an intracellular domain (ICD; ICD has not been resolved in the crystal structure). An
arrow indicates the direction of cation movement through the central pore. The ribbon
representation of the nAChR used the coordinates from the X-ray crystallography structure of
the α4β2 nAChR (PDB: 5KXI). The membrane is represented by a purple rectangle and the
extracellular (Ext.) and intracellular (Int.) sides of the membrane are indicated. B: Structure of
the agonist binding site in the ECD, which is at the interface between a “principal” subunit
(green) and a “complementary” subunit (cyan). The binding site is occupied by nicotine
(orange). The ECD of each subunit displays one α-helix and 10 β-strands (β1 to β10), and the
A-, B- , C- and F-loops are indicated. C: Illustration of the two main stoichiometries of
homopentameric α3β4 nAChRs and identification of the functional binding sites. The
illustration represents the nAChR as seen from the extracellular side and parallel to the
membrane; the pore is in the center of the pentamer. The C-loop of each subunit is indicated
by a curved line. The α3(+)β4(−) and α3(+)α3(−) agonist binding sites are indicated by orange
and green discs, respectively. D: Amino acid sequence of the disulfide isomers of AuIB. Cys
residues are numbered with Roman numerals (I–IV) and the disulfide bonds are shown as
orange sticks. E: Three-dimensional NMR solution structures of gAuIB (PDB: 1MXN) and
rAuIB (PDB: 1MXP).

Fig. 2. Secondary Hα chemical shifts (∆δHα) of gAuIB, rAuIB and their variants (panels A, B
and C) and analysis of the conformation of [P7A]rAuIB (panels D, E and F). A, B and C:
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Secondary Hα chemical shifts of gAuIB, [P7A]gAuIB, rAuIB, and the rAuIB variants. The
sequence of AuIB is indicated at the bottom. The dashed lines at 0.1 ppm and -0.1 ppm
indicate the cut-off considered for assessing regular secondary structure content (above 0.1
ppm is β-strand and under -0.1 ppm is α-helix). D: Co-elution profile by reversed-phase
HPLC of [P7A]rAuIB and [P7A]gAuIB monitored by absorbance at 214 nm. E: Secondary
structure content of rAuIB and [P7A]rAuIB monitored over 200 ns molecular dynamics
simulations. The positions in the sequence are on the y-axis. The secondary structure around
position 7 is highlighted using a red dashed line. F: Root-mean-square fluctuation (RMSF) of
the Cα of each position of rAuIB and [P7A]rAuIB over 200 ns molecular dynamics
simulations. The RMSF was computed by fitting the Cα of the molecules to the first frame of
each simulation.

Fig. 3. Activity of gAuIB, rAuIB and alanine mutants of rAuIB at the rat α3β4 nAChR. A and
B: Bar graphs showing relative ACh-evoked peak current inhibition of rat α3β4 nAChR
(α3:β4 = 10:1) by rAuIB analogues and gAuIB compared with rAuIB. In A, the peptides were
tested at 1 µM, except gAuIB (3 µΜ). In B, the peptides were tested at 100 µM. The dashed
lines indicate relative current amplitude in the presence of rAuIB. C: Superimposed
representative traces of ACh-evoked currents mediated by rat α3β4 nAChR in the absence
(black) and presence (red) of 1 µM (left) or 100 µM (right) [S4A]rAuIB. D: Concentrationresponse relationship of relative ACh-evoked current amplitude mediated by rat α3β4 nAChR
(α3:β4 = 10:1) in the presence of [S4A]rAuIB (10 nM−100 µM) giving an IC50 of
441.8 ± 98.5 nM. Whole-cell currents at rat α3β4 were activated by 50 µM ACh. Relative
current amplitude values are mean ± standard error of the mean; n = 5−9. The difference
between the relative current amplitude of rAuIB and each variant was evaluated using the
unpaired Student’s t-test; * indicates a p < 0.05.
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Fig. 4. Molecular models of complexes between α3β4 nAChR and gAuIB (A), rAuIB (B),
[S4A]rAuIB (C), or [F9A]rAuIB (D). The evolution of a selection of distances indicative of
hydrogen bonds between pairs of residues at the interface is shown at the bottom for each
model. The α3(+) subunit is shown in green, the α3(−) or β4(−) subunit is shown in cyan, the
peptides are shown in orange, and the disulfide bonds are shown in yellow. Hydrogen bonds
monitored in the bottom panel are displayed as dotted black lines on the structure. Interactions
between charged side chains are circled with a dotted red line. The distances were evaluated
during the last 20 ns of each molecular dynamics simulation. The label for each distance
comprises the residue of the toxin followed by the residue of the receptor. A dashed line at
3.2 Å indicates the upper-limit between the donor and acceptor atoms involved in a hydrogen
bond. Panel B inset shows an overlay of the binding modes of rAuIB (orange) and gAuIB
(white). Panel D inset shows that the C-loop in the [F9A]rAuIB molecular model (orange)
moves outward compared to the C-loop in the model of the rAuIB/α3β4 nAChR complex
(white).
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Table 1. Amino acid sequences of gAuIB, rAuIB and variants synthesized and characterized
in this study.
Peptide name

Theoretical massa

Sequence

Observed massa

gAuIB

GCCSYPPCFATNPDC-NH2

1572.8

1572.2

rAuIB

GCCSYPPCFATNPDC-NH2

1572.8

1572.4

[G1A]rAuIB

ACCSYPPCFATNPDC-NH2

1586.8

1586.6

[S4A]rAuIB

GCCAYPPCFATNPDC-NH2

1556.8

1556.6

[Y5A]rAuIB

GCCSAPPCFATNPDC-NH2

1480.7

1480.3

[P6A]rAuIB

GCCSYAPCFATNPDC-NH2

1546.7

1546.4

[P7A]rAuIB

GCCSYPACFATNPDC-NH2

1546.7

1546.4

[F9A]rAuIB

GCCSYPPCAATNPDC-NH2

1496.7

1496.3

[T11A]rAuIB

GCCSYPPCFAANPDC-NH2

1542.8

1542.4

[N12A]rAuIB

GCCSYPPCFATAPDC-NH2

1529.8

1529.4

[P13A]rAuIB

GCCSYPPCFATNADC-NH2

1546.8

1546.4

[D14A]rAuIB

GCCSYPPCFATNPAC-NH2

1528.8

1528.4

[P7A]gAuIB

GCCSYPACFATNPDC-NH2

1546.7

1546.2

a

Average mass in Dalton.
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